EUCTR2005-000970-37-ES进行中（未招募）1 期
Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin (FOLFOX 4) plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer - OPUS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Signed written informed consents (first and second)
- •·Inpatient or outpatient =18 years of age
- •·Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum
- •·1st occurrence of metastatic disease (not curatively resectable)
- •·Immunohistochemical evidence of epidermal growth factor receptor expression in tumor tissue
- •·Life expectancy of at least 12 weeks
- •·Presence of at least 1 bi-dimensionally measurable index lesion (not in an irradiated area)
- •·ECOG performance status of = 2 at study entry
- •·Effective contraception for both male and female subjects if the risk of conception exists
- •·White blood cell count (WBC) = 3x109/L with neutrophils =1.5x109/L, platelet count > 100x109/L, hemoglobin = 6.21 mmol/L (10 g/dL)
- •·ASAT and ALAT = 2.5 x upper reference range, or = 5 x upper reference range in case of liver metastasis
- •·Serum creatinine = 1.5 x upper reference range
- •·Recovery from relevant toxicity to previous treatment before study entry
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Previous exposure to epidermal growth factor receptor-targeting therapy·Previous oxaliplatin-based chemotherapy
- •·Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment
- •·Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before randomization
- •·Concurrent chronic systemic immune therapy or hormone therapy not indicated in this study protocol except for physiologic replacement
- •·Known hypersensitivity reaction to any of the components of study treatments
- •·Pregnancy (absence to be confirmed by ß HCG test) or lactation period·Brain metastasis and/or leptomeningeal disease (known or suspected)·Clinically relevant coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
- •·Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
- •·Previous malignancy other than colorectal cancer in the last 5 years except basal cell cancer of the skin or pre-invasive cancer of the cervix
- •·Known alcohol or drug abuse·Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent·Participation in another clinical study within the 30 days before randomization
- •·Significant disease which, in the investigator’s opinion, would exclude the subject from the study
- •·Peripheral neuropathy > grade 1
- •·Legal incapacity or limited legal capacity
研究者
相似试验
进行中（未招募）
1 期
Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing advanced NSCLC - FLEXEpidermal growth factor receptor-expressing advanced non-small cell lung cancer.MedDRA version: 7.0 Classification code 10061873EUCTR2004-001105-96-GBMerck KGaA
进行中（未招募）
不适用
Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer. - CRYSTAEUCTR2004-000137-11-HUMerck KGaA1,300
进行中（未招募）
不适用
Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer. - CRYSTAFirst-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancerMedDRA version: 7.0Level: LLTClassification code 10052362EUCTR2004-000137-11-LTMerck KGaA1,300
进行中（未招募）
不适用
Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth receptor-expressing metastatic colorectal cancerepidermal growth receptor-expressing metastatic colorectal cancer.MedDRA version: 6.1Level: PTClassification code 10052358EUCTR2004-000137-11-ITMERCK S.P.A.1,080
进行中（未招募）
1 期
Open, randomized, controlled, multicenter study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan in metastaic colorectal cancer as first-line treatment.First-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000137-11-ESMerck KGaA